If MNTA's claim is considered equal to Classen, the stock is damaged greatly. Classen's "invention" is a dose schedule. Hardly much of anything. For MNTA, All the work that went into developing a method for determining the contents of an extremely complex chemical was essentially given-away with the patent publication. The Solicitor General is not helping, the refusal to en bank is not helping and I have little faith in the Supreme Court to really understand how MNTA has been harmed. The inventors have made millions already. If the company was too stupid to keep their secret behind closed doors, then we investors have bought into a dog that just won't hunt.